Table of contents
January 2006 Volume 2 No 1
Viewpoint
Graves' hyperthyroidism: how long should antithyroid drug therapy be continued to achieve remission?
2Although medication for Graves' hyperthyroidism can be withdrawn without adverse effects for the patient, the data regarding the optimal duration of therapy are still unsatisfactory. This Viewpoint discusses how long treatment for Graves' disease should be continued and how withdrawal of antithyroid drugs might affect remission and relapse.
Research Highlights
End-stage renal disease in patients with type 1 diabetes
4Hypogonadotropic hypogonadism and abnormal olfactory-bulb development in CHARGE syndrome
4Night-time salivary cortisol is an excellent screening test for Cushing syndrome
4The mediating role of abdominal visceral fat in nonalcoholic hepatic steatosis
5Patients more at risk of developing type 2 diabetes after first myocardial infarction
5Vildagliptin successful in treating type 2 diabetes
6Improvement in NAFLD after laparoscopic weight-loss surgery
6Exenatide and insulin glargine are equally effective in patients with suboptimally controlled type 2 diabetes
7PTHrP modifies the efficacy of administered PTH 1–34: implications for osteoporosis treatment
7doi:10.1038/ncpendmet0065 | Full Text | PDF (106K)
Extrathyroidal types 1 and 2 iodothyronine deiodinase as sources of plasma T3
8doi:10.1038/ncpendmet0066 | Full Text | PDF (104K)
Prophylactic thyroidectomy: effective against medullary thyroid carcinoma in children
9Practice Points
Can dopamine agonists prevent postoperative remnant enlargement in nonfunctioning pituitary adenomas?
10Does the nadir growth-hormone level predict response to somatostatin-analogue therapy?
12Should children with osteogenesis imperfecta be treated with bisphosphonates?
14doi:10.1038/ncpendmet0075 | Full Text | PDF (101K)
Is endoscopic adrenalectomy the treatment of choice for large primary adrenal tumors?
16Reviews
Endocrine aspects of acute and prolonged critical illness
20Neuroendocrine responses differ markedly in chronic critical illness compared with acute illness, and the chronic response may be harmful. Hyperglycemia is a major risk factor, and control of blood glucose is important. Because hypothalamic–pituitary axes interact during chronic illness, validating new therapies aimed at correcting multiple endocrine pathways seems warranted.
doi:10.1038/ncpendmet0071 | Full Text | PDF (293K)
Drug Insight: recent advances in male hormonal contraception
32Administration of testosterone to men markedly reduces sperm counts and is a very efficient and well tolerated method of contraception. Combinations with progestogens or with gonadotropin-releasing hormone antagonists are even more effective and suggest that hormonal contraception in men is feasible and may be as effective as the currently used methods.
doi:10.1038/ncpendmet0069 | Full Text | PDF (223K)
Drug Insight: small-molecule inhibitors of protein kinases in the treatment of thyroid cancer
42Thyroid cancer is the commonest endocrine malignancy, and drugs that target protein kinases offer a new approach in combating this and other malignancies. This review describes the various kinase targets in thyroid cancers, and details the inhibitors of the kinases RET and BRAF that are now in clinical trials.
doi:10.1038/ncpendmet0073 | Full Text | PDF (246K)
